Published in Atherosclerosis on July 01, 1991
Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA (2009) 5.63
Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol (2004) 1.48
Monogenic dyslipidemias: window on determinants of plasma lipoprotein metabolism. Am J Hum Genet (2001) 0.97
Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein(a) phenotypes. Am J Hum Genet (1992) 0.92
Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a). Proc Natl Acad Sci U S A (1995) 0.86
LDL-apheresis: technical and clinical aspects. ScientificWorldJournal (2012) 0.85
Lipoprotein(a) in cardiovascular diseases. Biomed Res Int (2012) 0.83
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res (2016) 0.83
Effects of renal replacement therapy on plasma lipoprotein(a) levels. Am J Nephrol (2007) 0.81
Relook at lipoprotein (A): independent risk factor of coronary artery disease in north Indian population. Indian Heart J (2014) 0.81
Serum lipoprotein(a) concentrations are related to coronary disease progression without new myocardial infarction. Br Heart J (1995) 0.78
Lipoprotein(a)-clinical aspects and future challenges. Clin Res Cardiol Suppl (2015) 0.77
The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis (2016) 0.76
New paradigms in preventive cardiology: unconventional coronary risk factors. Ochsner J (2000) 0.76
Serum Lp(a) lipoprotein concentration and outcome of thrombolytic treatment for myocardial infarction. Br Heart J (1994) 0.75
The effects of long term storage on serum Lp(a) levels. Atherosclerosis (1992) 0.75
Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med (1987) 13.50
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet (2005) 13.18
Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet (1988) 7.59
Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet (2001) 6.82
Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med (1992) 5.65
Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation (1992) 4.96
Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Natl Cancer Inst (1998) 4.72
Randomised trial of alpha-tocopherol and beta-carotene supplements on incidence of major coronary events in men with previous myocardial infarction. Lancet (1997) 4.19
Mapping genes for NIDDM. Design of the Finland-United States Investigation of NIDDM Genetics (FUSION) Study. Diabetes Care (1998) 3.99
Prevention of progression of coronary atherosclerosis by treatment of hyperlipidaemia: a seven year prospective angiographic study. Br Med J (Clin Res Ed) (1984) 3.62
Relation between QT intervals and heart rates from 40 to 120 beats/min in rest electrocardiograms of men and a simple method to adjust QT interval values. J Am Coll Cardiol (1994) 3.35
Altered absorption of digoxin in patients given propantheline and metoclopramide. Lancet (1973) 3.04
Adipose tissue isomeric trans fatty acids and risk of myocardial infarction in nine countries: the EURAMIC study. Lancet (1995) 3.03
Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med (1998) 3.01
Alpha-Tocopherol and beta-carotene supplements and lung cancer incidence in the alpha-tocopherol, beta-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst (1996) 2.98
Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA (1988) 2.89
Measurement of the angina threshold using atrial pacing. A new technique for the study of angina pectoris. Cardiovasc Res (1967) 2.84
Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease. Neuroepidemiology (1998) 2.83
Blood group M specific haemagglutinin in pyelonephritogenic Escherichia coli. Lancet (1982) 2.56
Reproducibility and validity of dietary assessment instruments. I. A self-administered food use questionnaire with a portion size picture booklet. Am J Epidemiol (1988) 2.53
Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr (1995) 2.25
Type 2 diabetes: evidence for linkage on chromosome 20 in 716 Finnish affected sib pairs. Proc Natl Acad Sci U S A (1999) 1.91
Preceding infection as an important risk factor for ischaemic brain infarction in young and middle aged patients. Br Med J (Clin Res Ed) (1988) 1.90
Lycopene and myocardial infarction risk in the EURAMIC Study. Am J Epidemiol (1997) 1.84
Infections, inflammation, and the risk of coronary heart disease. Circulation (2000) 1.77
Familiality of quantitative metabolic traits in Finnish families with non-insulin-dependent diabetes mellitus. Finland-United States Investigation of NIDDM Genetics (FUSION) Study investigators. Hum Hered (1999) 1.76
Effects of supplemental alpha-tocopherol and beta-carotene on colorectal cancer: results from a controlled trial (Finland) Cancer Causes Control (2000) 1.75
Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care (1992) 1.75
Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol (1999) 1.70
Dissecting the role of the golgi complex and lipid rafts in biosynthetic transport of cholesterol to the cell surface. Proc Natl Acad Sci U S A (2000) 1.67
Multifactorial primary prevention of cardiovascular diseases in middle-aged men. Risk factor changes, incidence, and mortality. JAMA (1985) 1.66
Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet (1982) 1.66
Serum complement and familial combined hyperlipidemia. Atherosclerosis (1997) 1.64
Soluble urokinase-type plasminogen activator receptor in patients with suspected infection in the emergency room: a prospective cohort study. J Intern Med (2012) 1.59
Elevated fasting plasma insulin in a general aged population: an innocent companion of cardiovascular diseases. J Am Geriatr Soc (1997) 1.59
Relationship of skeletal muscle fiber type to serum high density lipoprotein cholesterol and apolipoprotein A-I levels. Atherosclerosis (1991) 1.56
Serum-digoxin concentrations during treatment with different preparations. Lancet (1971) 1.56
Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease. Clin Genet (1974) 1.54
Reproducibility and validity of dietary assessment instruments. II. A qualitative food frequency questionnaire. Am J Epidemiol (1988) 1.53
Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia (2010) 1.53
Life-style factors and risk for abdominal aortic aneurysm in a cohort of Finnish male smokers. Epidemiology (2001) 1.52
Linkage of familial combined hyperlipidaemia to chromosome 1q21-q23. Nat Genet (1998) 1.52
Combined parasympathetic and beta-receptor blockade as a clinical test. Acta Med Scand (1967) 1.51
Apolipoprotein E polymorphism in the Finnish population: gene frequencies and relation to lipoprotein concentrations. J Lipid Res (1986) 1.50
Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis (1995) 1.48
Joint effects of an aldosterone synthase (CYP11B2) gene polymorphism and classic risk factors on risk of myocardial infarction. Circulation (1999) 1.48
Current characteristics and outcome of cytomegalovirus infections after kidney transplantation. Transpl Infect Dis (2014) 1.46
Adipose tissue trans fatty acids and breast cancer in the European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. Cancer Epidemiol Biomarkers Prev (1997) 1.46
Effect of diet on serum lipoproteins in a population with a high risk of coronary heart disease. N Engl J Med (1982) 1.45
Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem (1993) 1.43
An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta (1975) 1.43
Prevalence and predictors of audible physiological third heart sound in a population sample aged 36 to 37 years. Circulation (1994) 1.43
The hypothalamus-pituitary-gonad axis and testicular function in male patients after treatment for haematological malignancies. J Intern Med (1998) 1.43
The OSBP-related protein family in humans. J Lipid Res (2001) 1.40
Accuracy and precision of quantitative arteriography in the evaluation of coronary artery disease after coronary bypass surgery. A validation study. Int J Card Imaging (1994) 1.39
Purification and characterization of lipoprotein lipase from pig adipose tissue. J Biol Chem (1974) 1.39
Apolipoprotein E polymorphism predicts death from coronary heart disease in a longitudinal study of elderly Finnish men. Circulation (1995) 1.35
myc oncogenes: activation and amplification. Biochim Biophys Acta (1987) 1.34
Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis (1994) 1.32
Controlled trial of alpha-tocopherol and beta-carotene supplements on stroke incidence and mortality in male smokers. Arterioscler Thromb Vasc Biol (2000) 1.32
Characterization of two lipoproteins containing apolipoproteins B and E from lesion-free human aortic intima. J Lipid Res (1988) 1.31
Activation and phosphorylation of purified adipose tissue hormone-sensitive lipase by cyclic AMP-dependent protein kinase. Biochim Biophys Acta (1971) 1.31
Fatty-acid composition of serum lipids predicts myocardial infarction. Br Med J (Clin Res Ed) (1982) 1.30
The mechanism of the remodeling of high density lipoproteins by phospholipid transfer protein. J Biol Chem (2001) 1.30
Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension (1995) 1.30
Efficacy of gemfibrozil in dyslipidaemic subjects with suspected heart disease. An ancillary study in the Helsinki Heart Study frame population. Ann Med (1993) 1.29
The impact of phospholipid transfer protein (PLTP) on HDL metabolism. Atherosclerosis (2001) 1.29
Cigarette smoking and alcohol consumption as risk factors for aneurysmal subarachnoid hemorrhage. Stroke (1993) 1.26
Apolipoprotein E and B polymorphisms--longevity factors assessed in nonagenarians. Atherosclerosis (1994) 1.25
Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype. J Clin Invest (1987) 1.25
Postheparin plasma lipoprotein lipase and hepatic lipase in diabetes mellitus. Relationship to plasma triglyceride metabolism. Diabetes (1977) 1.23
Effect of vitamin E and beta carotene on the incidence of primary nonfatal myocardial infarction and fatal coronary heart disease. Arch Intern Med (1998) 1.21
Occupational rheumatic diseases and upper limb strain in manual jobs in a light mechanical industry. Scand J Work Environ Health (1979) 1.21
Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation (1995) 1.21
Genomewide scan for familial combined hyperlipidemia genes in finnish families, suggesting multiple susceptibility loci influencing triglyceride, cholesterol, and apolipoprotein B levels. Am J Hum Genet (1999) 1.21
The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med (1994) 1.20